997P Ongoing phase I trial results of AMT-253, a first-in-class MUC18-targeting antibody-drug conjugate in patients with melanoma and other advanced solid tumors.
Saved in:
| Title: | 997P Ongoing phase I trial results of AMT-253, a first-in-class MUC18-targeting antibody-drug conjugate in patients with melanoma and other advanced solid tumors. |
|---|---|
| Authors: | Guo, J.1 (AUTHOR), Cui, C.1 (AUTHOR), Kelly, R.2 (AUTHOR), Gao, B.3 (AUTHOR), Kwatra, V.4 (AUTHOR), Chen, Y.5 (AUTHOR), Richardson, G.6 (AUTHOR), Coward, J.I.7 (AUTHOR), Sabanathan, D.8 (AUTHOR), Jiang, Y.9 (AUTHOR), Wu, D.10 (AUTHOR), li, K.11 (AUTHOR), Sutherland, S.12 (AUTHOR), Abbas, N.13 (AUTHOR), Wang, S.14 (AUTHOR), Liang, X.15 (AUTHOR), Liu, X.16 (AUTHOR), Zhang, B.17 (AUTHOR), Liu, S-H.18 (AUTHOR), Meng, X.17 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS651-S652. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.1566 |
